MedTrace Logo

Mechanism Study of Sulforaphane in ASD Improvement

NCT07047976 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-09-04

No results posted yet for this study

Summary

The goal of this clinical trial is to find out if sulforaphane (SFN) can improve social skills and behavior in people with Autism Spectrum Disorder (ASD). ASD is a developmental disorder that affects how children and teenagers interact with others. The number of people diagnosed with ASD has been rising, putting a lot of pressure on families and society. The investigators hope this study will lead to new treatments.

The main questions the investigators want to answer are:

Can sulforaphane help improve social communication in people with ASD? How does sulforaphane affect the balance of certain chemicals in the brain?

The investigators will recruit 50 participants aged 12 to 34 diagnosed with ASD and 30 healthy volunteers for comparison. Participants will:

Take 3 capsules of sulforaphane each day for 8 weeks. Complete regular psychological tests, undergo brain scans, and have their brain activity monitored to assess the treatment's effectiveness.

Through this study, the investigators aim to discover the potential benefits of sulforaphane for individuals with ASD and provide new insights for future treatment options.

Conditions

Interventions

DIETARY_SUPPLEMENT

Sulforaphane

This intervention involves the administration of Sulforaphane, a compound derived from glucoraphanin found in cruciferous vegetables. Participants will receive Avmacol® tablets, each containing 30 mg of glucoraphanin (approximately 68 μmol per tablet). They will take 3 tablets daily, resulting in a total daily dosage of approximately 90 μmol of Sulforaphane. The intervention will last for 8 weeks, during which participants will be monitored for clinical and biological outcomes.

Sponsors & Collaborators

  • Jian-Jun Ou

    lead OTHER

Principal Investigators

  • Jianjun Ou, Doctor · Central South University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
34 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2025-07-01
Completion
2026-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07047976 on ClinicalTrials.gov